Medical Cost Analysis of Implantable Cardioverter Defibrillators for Primary Prevention Among Cardiac Arrest Patients
Circulation Journal · 2025
DOI: 10.1253/circj.cj-25-0195 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Circulation Journal, 2025. Verfasst von Yusuke Kondo und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine. Hauptthemen laut MEDLINE: Defibrillators, Implantable, Primary Prevention, Death, Sudden, Cardiac, Heart Arrest. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben.
Themen: Reanimation
Abstract (Originalsprache)
BACKGROUND: In Japan, the implantation of implantable cardioverter defibrillators (ICD) for the primary prevention of sudden cardiac death (SCD) is not covered by insurance reimbursement, and the underuse of ICDs has been noted. Therefore, this study analyzed the medical costs incurred due to a lack of primary prevention ICD therapy for SCD. METHODS AND RESULTS: This retrospective cohort study analyzed data from 4 advanced critical care centers between January 2020 and December 2024. From a database of 3,606 cases of cardiac arrest, there were 348 patients with a documented rhythm at the time of arrest that could have been treated with an ICD. Of these patients, 43 (12.4%) had documented evidence of heart failure treatment and were eligible for ICD implantation before experiencing a cardiac arrest. The total mean (±SD) medical cost for these patients was US $11,679±14,666 (¥1,775,150±2,229,272). CONCLUSIONS: In this multicenter retrospective analysis, we identified a subset of patients who were eligible for primary prevention ICD therapy but did not receive it prior to experiencing sudden cardiac arrest. These cases were associated with substantial post-arrest medical costs. Our findings highlight the potential clinical and economic impact of the underutilization of ICDs in Japan and suggest that broader implementation of guideline-directed ICD therapy for primary prevention may reduce both mortality and healthcare expenditure.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine.
- Department of Cardiology, Angiology and Intensive Care Medicine, Deutsches Herzzentrum der Charité.
- Department of Biostatistics, Graduate School of Medicine, Saitama Medical University.
- TXP Medical Co. Ltd.
- Cardiac Rhythm Management, Medtronic plc.
- Healthcare Economics and Government Affairs, Medtronic Japan Co., Ltd.
Zitieren
APA
Kondo, Y., Chiba, T., Osawa, M., Kawasaki, Y., Goto, T., Coles, J. A., Ono, S., Imai, K., Takagi, M., Matoba, S., Kobayashi, Y., & Tada, H. (2025). Medical Cost Analysis of Implantable Cardioverter Defibrillators for Primary Prevention Among Cardiac Arrest Patients. Circulation Journal. https://doi.org/10.1253/circj.cj-25-0195
Vancouver
Kondo Y, Chiba T, Osawa M, Kawasaki Y, Goto T, Coles JA, et al. Medical Cost Analysis of Implantable Cardioverter Defibrillators for Primary Prevention Among Cardiac Arrest Patients. Circulation Journal. 2025. doi:10.1253/circj.cj-25-0195
BibTeX
@article{Kondo2025,
author = {Kondo, Yusuke and Chiba, Toshinori and Osawa, Maiko and Kawasaki, Yohei and Goto, Tadahiro and Coles, James A and Ono, Sayaka and Imai, Katsuhiko and Takagi, Masahiko and Matoba, Satoaki and Kobayashi, Yoshio and Tada, Hiroshi},
title = {Medical Cost Analysis of Implantable Cardioverter Defibrillators for Primary Prevention Among Cardiac Arrest Patients},
journal = {Circulation Journal},
year = {2025},
doi = {10.1253/circj.cj-25-0195}
}
EUVIMED